Group 1 - On January 16, Madi Technology's stock fell by 3.38%, with a trading volume of 331 million yuan. The margin trading data showed a financing buy amount of 31.92 million yuan and a financing repayment of 36.84 million yuan, resulting in a net financing buy of -4.92 million yuan. As of January 16, the total margin trading balance was 262 million yuan [1] - The financing buy on January 16 was 31.92 million yuan, with a current financing balance of 262 million yuan, accounting for 5.44% of the circulating market value. This financing balance is above the 60th percentile level over the past year, indicating a high position [1] - In terms of securities lending, on January 16, Madi Technology had no shares repaid and sold 900 shares, amounting to 14,200 yuan at the closing price. The remaining securities lending volume was 10,100 shares, with a balance of 158,900 yuan, exceeding the 90th percentile level over the past year, indicating a high position [1] Group 2 - As of September 30, Madi Technology had 38,900 shareholders, an increase of 7.17% from the previous period. The average circulating shares per person were 7,864, a decrease of 6.69% [2] - For the period from January to September 2025, Madi Technology achieved an operating income of 22.3 million yuan, a year-on-year decrease of 38.13%. However, the net profit attributable to the parent company was 34.27 million yuan, reflecting a year-on-year growth of 120.49% [2] - In terms of dividends, Madi Technology has distributed a total of 71.36 million yuan since its A-share listing, with no dividends paid in the last three years [3]

Core Viewpoint - The company is accelerating the integration of AI technology with its core product system in clinical information systems, enhancing its smart medical products with AI capabilities [1] Group 1: AI Integration in Clinical Systems - The company is advancing the application of AI large models in clinical information systems [1] - AI upgrades are being implemented in three major systems: anesthesia, critical care, and emergency rescue [1] - Achievements include clinical decision support upgrades, risk warning, electronic medical record generation, and regional medical collaboration [1] Group 2: Development in Health Robotics - The company has developed the Youmai AI voice assistant interaction system, which supports multiple large model integrations such as DeepSeek, Doubao, and Qianwen [1] - The system is capable of health Q&A, emotional companionship, and health consultations [1]

Core Viewpoint - The company, MediTech (603990), is integrating its anesthesia, critical care, and emergency rescue systems with multiple large models, continuously upgrading its AI capabilities to enhance healthcare processes [1] Group 1: Anesthesia AI Assistant - The company has launched an AI assistant for anesthesia that covers the entire process from preoperative assessment to intraoperative support and postoperative knowledge services [1] - The AI assistant automates preoperative evaluations, provides intelligent safeguards during surgery, and offers specialized knowledge services [1] Group 2: Critical Care Products - The critical care products support both cloud and private deployment, balancing intelligence with data security [1] Group 3: Emergency Clinical Information System - The emergency clinical information system has achieved breakthroughs in intelligent triage, diagnostic assistance, risk warning, and electronic medical record generation [1] Group 4: Robotics and AI Integration - The company is actively promoting its health and wellness robot business, with its self-developed AI voice assistant capable of health Q&A, emotional companionship, and wellness consultations [1] - The AI voice assistant supports integration with various large models, including DeepSeek, Doubao, and Qianwen [1]

Core Insights - The simultaneous focus of Ant Group and OpenAI on the healthcare sector indicates a significant shift of AI from general models to specialized applications, particularly in AI healthcare, moving from concept validation to large-scale implementation [1] Group 1: AI Integration in Healthcare - The rapid evolution of large model technology is expanding the boundaries of AI applications in healthcare, with AI expected to enhance clinical decision-making, process management, and grassroots medical capabilities, thereby improving overall healthcare service efficiency and quality [2] - The company is accelerating the integration of AI technology with its core product system, completing AI upgrades across anesthesia, critical care, and emergency systems, while developing embodied intelligent AI products with capabilities such as diagnostic assistance and emotional companionship [2] Group 2: Data Management and Challenges - The company collaborates with multiple hospitals to enhance medical data security and operational efficiency, aiming to create an innovative "smart anesthesia" management system that transitions from information-based to intelligent systems, driven by data for research and clinical decision-making [3] - A significant barrier to the widespread implementation of AI in healthcare is the isolation of high-value clinical data, which is often trapped within individual medical institutions due to privacy and compliance issues, hindering safe circulation and sharing [3] Group 3: Building a Trusted Data Space - The concept of a trusted medical data space is increasingly viewed as a critical infrastructure for connecting medical institutions, research innovation, and industrial applications, serving as the core source for AI healthcare development [4] - The company is advancing key technologies such as data desensitization and structured processing to activate vast amounts of internal hospital data for safe use in AI training, clinical research, and product iteration, marking the beginning of this initiative with a recent multimillion-dollar data center project [4] Group 4: Future of AI in Healthcare - The integration of AI in healthcare is becoming a crucial challenge, with the need to create a secure, compliant, and sustainable high-quality data ecosystem being essential for unlocking the future of clinical intelligence [5]

Core Viewpoint - The announcements detail the share reduction activities of major shareholders of Suzhou Medisun Medical Technology Co., Ltd., including the results of share reductions by major shareholders and the management of idle raised funds [1][2][8]. Shareholder Reduction Summary - Major shareholder Mr. Weng Kang held 20,857,003 shares, representing 6.81% of the total share capital before the reduction plan [1]. - Mr. Weng Kang's reduction plan involved selling up to 5,214,250 shares, not exceeding 25% of his holdings or 1.70% of the total share capital, from October 16, 2025, to January 15, 2026 [1]. - As of January 12, 2026, Mr. Weng Kang successfully reduced his holdings by 5,213,800 shares, accounting for 1.70% of the total share capital [1]. - Mr. Wu Di planned to reduce his holdings by up to 14,250 shares, not exceeding 25% of his holdings or 0.0047% of the total share capital, during the same period [2]. - Mr. Wu Di successfully reduced his holdings by 14,200 shares, representing 0.0046% of the total share capital [2]. Compliance and Issues - Mr. Weng Kang's share reduction included an incident on December 17, 2025, where he mistakenly increased his holdings by 10,900 shares, constituting a short-term trading behavior [2]. - The company board has emphasized the importance of compliance with trading regulations to prevent similar occurrences in the future [2]. Fund Management Summary - The company approved a plan to manage idle raised funds of up to RMB 200 million for cash management, ensuring it does not affect project progress or fund safety [5]. - As of December 31, 2025, the company redeemed a bank deposit of RMB 90 million, earning a return of RMB 22,500 [6]. - The remaining balance of idle raised funds for cash management was RMB 15 million, with no overdue products reported [6].

Summary of Key Points Core Viewpoint - Multiple shareholders across various companies are planning to reduce their stakes, indicating potential shifts in ownership and investor sentiment in the market [1]. Shareholder Reductions - Hengxuan Technology: Shareholders including Ningbo Yibifu plan to reduce their holdings by up to 1.50% [1]. - Guoxin Technology: Industry fund shareholders intend to reduce their stakes by up to 2.37% [1]. - Qusleep Technology: Shareholder Kuanzhai Cultural plans to reduce holdings by no more than 1.98% [1]. - Xinwei Communication: General Manager Peng Hao aims to reduce his stake by up to 1% [1]. - Guoanda: Shareholder Hong Junlong plans to reduce his holdings by up to 1.2761% [1]. - Zhuoyue New Energy: Controlling shareholders intend to reduce their stakes by up to 3.00% [1]. - Haibo Heavy Industry: Actual controller Zhang Haibo plans to reduce his stake by up to 3% [1]. - Sanyou Medical: Shareholders Xu Nong and Liu Mingyan plan to reduce their holdings by up to 2.00% [1]. - Saifen Technology: Multiple shareholders intend to reduce their stakes by up to 6% [1]. - Fangyuan Shares: Shareholder Betterry plans to reduce holdings by no more than 510.17 million shares [1]. - Qiutian Micro: Beihai Chengyu plans to reduce holdings by up to 0.83% [1]. - Diaoda Shares: Controlling shareholders plan to reduce their stakes by up to 3% [1]. - Maidi Technology: Shareholder Weng Kang plans to reduce holdings by 520.29 million shares [1]. Other Notable Events - *ST Yanshi: The company's stock may face delisting [1]. - Jin Yi Technology: The company has terminated the issuance of shares to specific targets and signed relevant termination agreements [1].

Core Viewpoint - The share reduction plan of Suzhou Mediston Medical Technology Co., Ltd. has been completed, with shareholders Weng Kang and Wu Di collectively reducing their shares by 5.228 million shares, cashing out approximately 77.95 million yuan [1][2]. Shareholder Reduction Plan Implementation Overview - The reduction plan was announced on September 17, 2025, with Weng Kang planning to reduce up to 5.2143 million shares (1.7024% of total shares) and Wu Di planning to reduce up to 14,300 shares (0.0047% of total shares) between October 16, 2025, and January 15, 2026 [2]. - By January 12, 2026, both shareholders had completed most of their reduction plans, with only 450 shares and 50 shares remaining untransferred [2]. Weng Kang's Reduction Details - Weng Kang reduced 5.2138 million shares, cashing out approximately 77.73 million yuan, with a reduction price range of 14.2 yuan to 16.37 yuan per share [3]. - After the reduction, Weng Kang's shareholding decreased from 20.857 million shares to 15.6541 million shares, reducing his ownership percentage from 6.8097% to 5.1110% [3]. Wu Di's Reduction Details - Wu Di reduced 14,200 shares through centralized bidding, cashing out 222,900 yuan at a single price of 15.70 yuan per share [4]. - Following the reduction, Wu Di's shareholding decreased from 57,000 shares to 42,800 shares, with his ownership percentage dropping from 0.0186% to 0.0140% [4]. Compliance and Operational Issues - During the reduction process, Weng Kang was found to have made an erroneous purchase of shares on December 17, 2025, violating relevant laws and regulations [5]. - Wu Di had previously made a similar mistake on July 21, 2023, but did not incur any profit from the subsequent sale, thus not needing to return any earnings to the company [5]. Completion Status of the Reduction - Both shareholders achieved the minimum reduction quantities as per their plans, and the reduction plan was not terminated early, indicating compliance with the reduction commitments [6][7].

Group 1 - The core point of the article is that Mr. Weng Kang has reduced his shareholding in Suzhou Medistone Medical Technology Co., Ltd. by 520.29 million shares, which triggered a 1% change in equity [1] - Before the reduction, Mr. Weng held 20.857 million shares, and after the reduction, he holds 15.6541 million shares [1] - The share reduction occurred between October 16, 2025, and January 12, 2026, through centralized bidding and block trading methods [1]

证券代码：603990 证券简称：麦迪科技 公告编号：2026-002 苏州麦迪斯顿医疗科技股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的提示性 公告 投资者及其一致行动人翁康保证向本公司提供的信息真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息 一致。 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 上述减持主体无一致行动人 二、 权益变动触及 1%刻度的基本情况 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）于 2025 年 9 月 17 日披露了《麦迪科技股东减持股份计划公告》（公告编号：2025-061），翁康 先生拟于 2025 年 10 月 16 日至 2026 年 1 月 15 日，以大宗交易、集中竞价方式 减持其所持有的公司股份合计不超过 5,214,250 股，拟减持股份不超过公司总股 本的 1.7024%。 | | □控股股东/实际控制人及其一致行动人 | | --- | --- | | | ☑其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东 ...

证券代码：603990 证券简称：麦迪科技 公告编号：2026-003 苏州麦迪斯顿医疗科技股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东及董监高持股的基本情况 截至本次减持计划实施之前，苏州麦迪斯顿医疗科技股份有限公司（以下简 称"公司"）股东翁康先生持有公司股份 20,857,003 股，占公司股本总数的 6.8097%。吴镝先生持有公司股份 57,000 股，占公司股本总数的 0.0186%。 减持计划的实施结果情况 公司于 2025 年 9 月 17 日披露了《麦迪科技股东减持股份计划公告》（公告 编号：2025-061），翁康先生拟在 2025 年 10 月 16 日至 2026 年 1 月 15 日以大宗 交易、集中竞价方式择机减持其所持公司股份合计不超过 5,214,250 股，即不超 过其持有公司股份总数的 25%，不超过公司总股本的 1.7024%。公司于 2026 年 1 月 12 日收到翁康先生的《股份减持结果告知函》，翁康先生于 20 ...